Literature DB >> 17470385

Effects of allopregnanolone on sedation in men, and in women on oral contraceptives.

F van Broekhoven1, T Bäckström, G van Luijtelaar, J K Buitelaar, P Smits, R J Verkes.   

Abstract

Allopregnanolone is a known GABA(A) receptor agonist not previously given to men, or to women using oral contraceptives (OC). The effects of metabolites of sex hormones on the GABA(A) receptor are different between men and women. OC are known to change GABA(A) receptor subunit composition. These factors might play a role in the differential effect of allopregnanolone in men and women, and in women with or without OC. To study the sedative effect of and sensitivity to allopregnanolone in men and in women with OC, nine healthy men (mean age 24.6 years) and nine healthy women on OC (mean age 21.8 years) were given three, increasing, intravenous dosages (0.015, 0.03, and 0.045 mg/kg) of allopregnanolone. Saccadic eye velocity (SEV), subjective ratings, and electroencephalography (EEG) were used to evaluate the response to allopregnanolone. Repeated blood samples for analyses of serum allopregnanolone levels were drawn throughout the study day. Allopregnanolone decreased SEV more in women than in men, and increased subjective ratings of 'sedation'. The results in women on OC are similar to earlier results in women without OC. Subjective ratings of 'contentedness' decreased in men but increased in women. Serum levels of allopregnanolone were more highly increased in men compared to women. Other pharmacokinetic parameters were not different between sexes. On the EEG, beta power increased in men. In conclusion, men and women on OC reacted differently to allopregnanolone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470385     DOI: 10.1016/j.psyneuen.2007.03.009

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  12 in total

1.  A randomized controlled trial of ganaxolone in posttraumatic stress disorder.

Authors:  Ann M Rasmusson; Christine E Marx; Sonia Jain; Gail M Farfel; Julia Tsai; Xiaoying Sun; Thomas D Geracioti; Mark B Hamner; James Lohr; Richard Rosse; Lanier Summerall; Jennifer C Naylor; Cristine Cusin; Ariel J Lang; Rema Raman; Murray B Stein
Journal:  Psychopharmacology (Berl)       Date:  2017-07-01       Impact factor: 4.530

2.  Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.

Authors:  Erika Timby; Torbjörn Bäckström; Sigrid Nyberg; Hans Stenlund; Anna-Carin N Wihlbäck; Marie Bixo
Journal:  Psychopharmacology (Berl)       Date:  2016-03-10       Impact factor: 4.530

Review 3.  Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

Authors:  Ariela Frieder; Madeleine Fersh; Rachel Hainline; Kristina M Deligiannidis
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

4.  Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis.

Authors:  Matthew M Ford; Ethan H Beckley; Jeffrey D Nickel; Sarah Eddy; Deborah A Finn
Journal:  Drug Alcohol Depend       Date:  2008-05-16       Impact factor: 4.492

5.  Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease.

Authors:  Ronald W Irwin; Jun Ming Wang; Shuhua Chen; Roberta Diaz Brinton
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-12       Impact factor: 5.555

6.  Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease.

Authors:  Ronald W Irwin; Christine M Solinsky; Carlos M Loya; Francesco G Salituro; Kathleen E Rodgers; Gerhard Bauer; Michael A Rogawski; Roberta Diaz Brinton
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 7.  Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.

Authors:  Ronald W Irwin; Christine M Solinsky; Roberta Diaz Brinton
Journal:  Front Cell Neurosci       Date:  2014-07-30       Impact factor: 5.505

8.  Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Authors:  Eric S Rosenthal; Jan Claassen; Mark S Wainwright; Aatif M Husain; Henrikas Vaitkevicius; Shane Raines; Ethan Hoffmann; Helen Colquhoun; James J Doherty; Stephen J Kanes
Journal:  Ann Neurol       Date:  2017-09-11       Impact factor: 10.422

9.  Brexanolone for the treatment of patients with postpartum depression.

Authors:  K E Morrison; A B Cole; S M Thompson; T L Bale
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

Review 10.  Allopregnanolone and neuroinflammation: a focus on multiple sclerosis.

Authors:  Farshid Noorbakhsh; Glen B Baker; Christopher Power
Journal:  Front Cell Neurosci       Date:  2014-06-03       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.